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Nontypeable Haemophilus influenzae is a major causative agent of bacterial otitis media in children. H.
influenzae Hap autotransporter protein is an adhesin composed of an outer membrane Hap␤ region and a
moiety of an extracellular internal 110-kDa passenger domain called HapS. The HapS moiety promotes
adherence to human epithelial cells and extracellular matrix proteins, and it also mediates bacterial aggregation and microcolony formation. A recent work (D. L. Fink, A. Z. Buscher, B. A. Green, P. Fernsten, and J. W.
St. Geme, Cell. Microbiol. 5:175-186, 2003) demonstrated that HapS adhesive activity resides within the
C-terminal 311 amino acids (the cell binding domain) of the protein. In this study, we immunized mice
subcutaneously with recombinant proteins corresponding to the C-terminal region of HapS from H. influenzae
strains N187, P860295, and TN106 and examined the resulting immune response. Antisera against the
recombinant proteins from all three strains not only recognized native HapS purified from strain P860295 but
also inhibited H. influenzae Hap-mediated adherence to Chang epithelial cells. Furthermore, when mice
immunized intranasally with recombinant protein plus mutant cholera toxin CT-E29H were challenged with
strain TN106, they were protected against nasopharyngeal colonization. These observations demonstrate that
the C-terminal region of HapS is capable of eliciting cross-reacting antibodies that reduce nasopharyngeal
colonization, suggesting utility as a vaccine antigen for the prevention of nontypeable H. influenzae diseases.
Nontypeable Haemophilus influenzae (NTHi), a nonencapsulated gram-negative bacterium, is the cause of a number of
human respiratory tract diseases, such as otitis media, sinusitis,
bronchitis, and pneumonia (15, 16). Otitis media is among the
most common infections in young children. By 3 years of age,
approximately 80% of children have had at least one episode
of acute otitis media (25). Recurring bouts of otitis media may
lead to significant hearing loss, which in turn may result in
developmental delay. A vaccine that prevents nontypeable H.
influenzae disease would provide major benefits to the health
of children and the general population.
The pathogenesis of H. influenzae disease begins with colonization of the nasopharynx. Subsequently, organisms spread
to other sites in the respiratory tract, including the middle ear,
sinuses, and lower airways (21). Based on in vitro and animal
studies, a number of factors appear to influence the process of
colonization. One such factor is the Hap adhesin, which promotes bacterial interaction with human respiratory epithelial
cells and extracellular matrix proteins as well as mediates bacterial aggregation and microcolony formation (10, 23).
Hap belongs to the autotransporter family of proteins common among gram-negative pathogens (9). It is synthesized as a

155-kDa precursor protein, which consists of an N-terminal
25-amino-acid signal peptide, an internal 110-kDa passenger
domain called HapS, and a C-terminal 45-kDa outer membrane domain called Hap␤ (9). HapS has serine protease activity and is released from the precursor protein via autoproteolysis. Of note, autoproteolysis is inhibited by secretory
leukocyte protease inhibitor, which is a natural component of
respiratory secretions. The HapS domain is responsible for all
the adhesive properties of Hap (10, 23). Furthermore, purified
HapS is immunogenic in mice, eliciting significant anti-HapS
antibody titers. In a mouse intranasal challenge model, animals
immunized with purified HapS from NTHi strain P860295 or
N187 in the presence of mutant cholera toxin CT-E29H as an
adjuvant are protected against nasopharyngeal colonization
(5). These findings suggest that HapS has potential as a vaccine
antigen against NTHi. However, the development of a HapSbased vaccine has been hindered by difficulties in purifying
adequate quantities of HapS from the bacterium and the tendency of this protein to self associate.
Fink et al. recently reported that the domain in Hap responsible for promoting adherence to epithelial cells resides in the
C-terminal 311 amino acids of HapS (6). Additional work revealed that this region mediates bacterial aggregation via
HapS-HapS interaction between molecules on neighboring organisms and is a part of the C-terminal 511 amino acids required for adherence to selected extracellular matrix proteins,
including fibronectin, laminin, and collagen IV (7). To address
whether the C-terminal 311 amino acids of HapS (the cell
binding domain [CBD]) are capable of eliciting a protective
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immune response, we prepared recombinant CBD (rCBD)
either from glutathione S-transferase (GST) fusion proteins or
from urea-solubilized inclusion bodies. Using the mouse intranasal challenge model, we found that immunization with rCBD
derived from three different NTHi strains leads to significant
reduction in nasopharyngeal colonization. These results should
facilitate efforts to develop a HapS-based vaccine to prevent
nontypeable H. influenzae disease.

mented with 1% glucose and ampicillin, and it was then diluted into fresh broth
to an optical density at 600 nm (OD600) of 0.1. The culture was incubated at 37°C
with shaking to an OD600 of 1. To induce the cells, the temperature was shifted
down to 28°C and 1 mM isopropyl-1-thio-␤-D-galactopyranoside (IPTG) was
added to the culture. Two hours later, cells were harvested by low-speed centrifugation. Cells from 1 liter of induced culture were resuspended in phosphatebuffered saline (PBS) containing 0.2% Triton X-100, 2 mM pefabloc (Boehringer
Mannheim, Indianapolis, Ind.), and 1 mM EDTA, and then they were lysed by
passing through a Microfluidizer (Microfluidics International Corp., Newton,
Mass.). Cell lysate was centrifuged at 10,000 ⫻ g for 20 min to remove cell debris.
The portion of GST fusion protein that remained in the supernatant was absorbed onto affinity matrix glutathione Sepharose 4B and cleaved with PreScission protease according to the manufacturer’s guide (Amersham Pharmacia
Biotech). Bound rCBD was eluted with 50 mM Tris buffer at pH 7.5 containing
150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), and 0.2% Triton
X-100. Eluted rCBD was concentrated to ⬃1 mg/ml with Triton X-100 adjusted
to 0.5%. The resulting rCBD preparation was stored at ⫺20°C. Protein concentrations were determined by using the modified method of Lowry (17).
As a negative control, E. coli BL21(DE23)/pLysS containing the plasmid
vector pGEX-6P-1 was grown and induced and a cell lysate was prepared as
described above. This induced E. coli cell lysate was subsequently used to generate a mouse polyclonal antiserum (see below).
Isolation of rCBDN187 from inclusion bodies. E. coli BL21(DE23)/
pLysS⫹pWV1024 was incubated at 37°C on SOB agar supplemented with 1%
glucose and ampicillin. Cells were then grown in SOB broth overnight and were
diluted into fresh SOB broth to an OD600 of 0.1. When the culture reached an
OD600 of 1 to 1.5, 1 mM IPTG was added. Two hours after induction with IPTG,
cells were harvested by low-speed centrifugation. Cells from 1 liter of induced
culture were resuspended in PBS containing 1% Triton X-100, 5 mM pefabloc,
4 mM EDTA, 0.2 mg of lysozyme/ml, and 5-g/ml concentrations of each DNase
and RNase. After incubation at 37°C for 1 h with gentle rocking, cells were lysed
by passing through a Microfluidizer, and the resulting cell lysate was centrifuged
at 10,000 ⫻ g for 20 min. The pellet composed mainly of rCBDN187 inclusion
bodies was resuspended in 0.1 M Tris buffer at pH 8 containing 6 M urea, 2 mM
EDTA, and 5 mM pefabloc. The inclusion bodies were extracted with urea at 4°C
overnight with rocking. The extract was then centrifuged at 36,000 ⫻ g for 20 min
to remove insoluble material. The supernatant containing urea-solubilized
rCBDN187 was adjusted with the same buffer to ⬃6 mg/ml and was stored at
⫺70°C.
Renaturation of urea-solubilized rCBDN187 involves diluting the denatured
protein into a buffer containing a high concentration of L-arginine (1, 2, 18).
Briefly, urea-solubilized rCBDN187 was first reduced with 0.3 M DTT for 2 h at
room temperature. The reduced protein was diluted 100-fold into a buffer consisting of 0.1 M Tris at pH 8, 2 mM EDTA, 3 mM DTT, 5 mM oxidized
glutathione (GSSG), 0.4 M L-arginine, 150 mM NaCl, 0.015% Triton X-100, and
2 mM pefabloc. Protein renaturation proceeded in this diluted state at 10°C for
4 days. Renatured rCBDN187 was concentrated to 1 mg/ml in ⬃0.5% Triton
X-100. Dialysis was carried out stepwise to reduce L-arginine from 0.4 M to 0.3
M to 0.2 M, and finally down to 0.1 M in a buffer consisting of 0.1 M Tris at pH
8, 150 mM NaCl, and 0.5% Triton X-100. The dialyzed protein solution was
centrifuged at 36,000 ⫻ g for 20 min to remove insoluble material. The final
renatured rCBDN187 was stored at ⫺20°C.
Purification of native Haps from H. influenzae strain P860295. Native HapS
(nHapS-P860295) was purified from the culture supernatant as described previously (5), with minor modifications. Briefly, bacteria were grown in 10 liters of
BHI broth for 18 h at 35°C with aeration. All the following steps were performed
at 4°C. Bacterial cells were removed by centrifugation at 10,000 ⫻ g. The culture
supernatant was concentrated 20-fold by using an Amicon stir cell and was
fractionated overnight with ammonium sulfate at 60% saturation. After centrifugation at 17,000 ⫻ g for 1 h, the precipitate was dissolved in 20 mM Tris buffer
at pH 7.4 containing 50 mM NaCl and 1 mM EDTA, dialyzed against the same
buffer, and then centrifuged at 100,000 ⫻ g for 1 h to remove insoluble material.
The resulting supernatant was loaded at a flow rate of 2 ml/min onto a 20-ml SP
Sepharose column (Amersham Pharmacia Biotech) equilibrated with the same
buffer. The column was washed until the OD280 reached the baseline, and
nHapS-P860295 was eluted at a flow rate of 3 ml/min with a linear gradient of NaCl
(from 55 to 500 mM) in 20 mM Tris at pH 7.5 with 1 mM EDTA. Based on
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels,
fractions containing nHapS-P860295 were pooled.
SDS-PAGE and Western blot analysis. SDS-PAGE was performed with 12%
gels according to the method of Laemmli (13). For Western blot analysis, proteins were transferred to nitrocellulose (Schleicher & Schull, Keene, N.H.) (27)
and probed with anti-GST antibody or MAb 314, a murine monoclonal antibody
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MATERIALS AND METHODS
Bacterial strains and plasmids. NTHi strains N187 (obtained from Eric Hansen, University of Texas), P861454, P860295 (obtained from Charles Brinton,
University of Pittsburgh), and SR7332 (11) were isolated from middle ear fluid
of children with acute otitis media. NTHi strain TN106 (obtained from Eric
Hansen) was isolated from a patient with pneumonia (19, 23). TN106.P2 is a
streptomycin-resistant derivative of TN106 described previously (5). DB117 is an
unencapsulated, recombination-deficient derivative of a serotype d H. influenzae
strain that contains a mutated hap gene and fails to express Hap (20). Strain
DB117/HapP860295 produces on its surface plasmid-encoded wild-type
HapP860295, and strain DB117/HapN187 produces plasmid-encoded wild-type
HapN187. DB117/pGJB103 contains the plasmid vector pGBJ103 and does not
express Hap (23). Escherichia coli strain Top10 was purchased from Invitrogen
(Carlsbad, Calif.), and strain BL21(DE3)/pLysS was purchased from Novagen
(Madison, Wis.). Plasmids pET17b and pGEX-6P-1 were purchased from Novagen and Amersham Pharmacia Biotech (Piscataway, N.J.), respectively. Plasmid pGJB103 is an H. influenzae-E. coli shuttle vector described previously (26).
Bacterial cultures. NTHi cells were grown on brain-heart infusion agar plates
supplemented with hemin and NAD (BHI-XV agar), on BBL CHOC II agar
plates (Becton Dickinson & Co., Cockeysville, Md.), or in brain-heart infusion
broth supplemented with hemin and NAD (BHI) as described previously (8). E.
coli cells were grown on SOB agar or in SOB broth (14) containing the appropriate antibiotic.
PCR primers, PCR amplification, and DNA sequencing. PCR primer oligonucleotides were synthesized on a PerSeptive Biosystems oligonucleotide synthesizer (Applied Biosystems, Foster City, Calif.) using ␤-cyanoethylphosphoramidite chemistry. PCRs were performed in ReddyMix PCR Master Mix (ABgene
House, Surrey, United Kingdom) on a Perkin-Elmer GeneAmp 2400 unit. A hot
start of 5 min at 95°C prior to amplification was followed by 30 cycles of 1 min
at 95°C, 1 min at 55°C, and 2 min at 72°C. DNA sequencing was carried out using
BigDye terminator chemistry with specifically designed primers on an Applied
Biosystems 377 automated DNA sequencer. Sequencher 4.0.5 software (Gene
Codes, Corp., Ann Arbor, Mich.) was used to analyze the DNA sequences.
Construction of plasmids for the expression of GST-rCBD fusion proteins.
GST-rCBD fusion proteins were made with plasmids that contain the hap gene
from NTHi strain N187, 860295, or TN106 (5). PCR was performed to amplify
the appropriate segment of the gene. The DNA segments include sequences
encoding residues 726 to 1036 from HapN187, residues 734 to 1040 from
HapP860295, and residues 728 to 1032 from HapTN106. PCR primers were designed to incorporate a BamHI site at the 5⬘ end and an XhoI site at the 3⬘ end
of each segment. Following amplification, PCR products were digested with
BamHI and XhoI and then were ligated into BamHI-XhoI-digested pGEX-6P-1
(Amersham Pharmacia Biotech), juxtaposing the hap fragments downstream of
the coding sequence for glutathione S-transferase and a PreScission protease
cleavage site. The resulting plasmids pGEXN187C⬘311, pGEXP860295C⬘307,
and pGEXTN106C⬘305 were transformed into E. coli BL21(DE3)pLysS by electroporation for expression of GST-rCBDN187, GST-rCBDP860295, and GSTrCBDTN106 fusion proteins.
Construction of a CBDN187 expression vector. Plasmid pJS106 (23), containing
the hap gene from strain N187, was used as a template for cloning the DNA
sequence encoding CBDN187. The PCR primers for amplifying the CBD coding
region are oligonucleotides 5⬘GATCGCTTAAGCTTCCCAAAAACACAAAT
CAAT3⬘ and 5⬘CCTTGTCAGCGTCGACTTATAACAGGCTTTGATCAGG
CAGGGTAT3⬘. The PCR products were purified and ligated to the T7 tag in the
expression vector pET17b. The ligation reaction was transformed into TOP10
cells, and transformants were screened by PCR for the correct insert, yielding
pWV1024. This plasmid was verified to have the correct nucleotide sequence and
was then transformed into E. coli BL21(DE3)pLysS for expression of rCBDN187.
Isolation of rCBD from GST fusion protein. E. coli BL21(DE23)/pLysS containing plasmid pGEX-N187C⬘311, pGEX-P860295C⬘307, or pGEXTN106C⬘305 was grown overnight at 37°C with shaking in SOB broth supple-
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RESULTS
Protein sequence alignment of CBD of H. influenzae. In an
earlier work, Fink et al. (6) established that the C-terminal 311
amino acids of HapS-N187 harbor the adhesive activity of the
protein. To determine the level of conservation of this region,
we used the AlignX program of VectorNTI, version 6.0, software to align the C-terminal end of HapS from three NTHi
strains. The analysis indicates that the CBD fragments from

FIG. 1. SDS-PAGE and Western blot analysis of rCBDP860295 generated from GST-rCBDP860295 fusion protein. (A) Coomassie-stained
SDS gel loaded with 5 g of rCBDP860295 (lane 2); lane 1 shows
Bio-Rad prestained low-molecular-mass markers (in kilodaltons).
(B) Western blot probed with MAb 314, showing GST-rCBDP860295
fusion protein and rCBDP860295. (C) Western blot probed with antiGST antibody, showing GST and GST-rCBDP860295 fusion protein.

strains P860295, TN106, and N187 are 97.1% similar and 81%
identical.
Antibody response elicited by rCBD generated from GST
fusion protein. rCBDP860295, rCBDTN106, and rCBDN187 were
generated from the soluble fraction of the respective GSTrCBD fusion proteins. As shown in Fig. 1A, rCBDP860295 is the
major protein in the affinity-purified preparation, with a purity
of ⬃60%. In Western blot analysis, rCBDP860295 reacts with
MAb 314 (Fig. 1B) but not with anti-GST antibody (Fig. 1C).
MAb 314 also detects small amounts of uncleaved GSTrCBDP860295, fusion protein cleaved at alternate sites, and degradation products of rCBDP860295 (Fig. 1B). Some of the minor
bands in Fig. 1A not recognized by MAb 314 or anti-GST
antibody probably represent contaminating E. coli proteins.
Similar patterns of reactivity are observed with rCBDTN106 and
rCBDN187 preparations derived from GST fusions (data not
shown).
Mouse antisera against the three rCBD fragments derived
from soluble GST fusion proteins were tested for antibody
response to nHapS purified from strain P860295. After one
immunization, the antisera had low titers toward nHapS-P860295
(data not shown). After a second immunization, high antibody
titers were detected in mice that received rCBDN187 and
rCBDP860295 and a relatively high titer was detected in mice
that received rCBDTN106 (Table 1), suggesting that rCBDN187
and rCBDTN106 are able to elicit antibodies that cross-react
with nHapS-P860295. Preimmune sera had antibody titers to
nHapS-P860295 of less than 100. Because the rCBD preparations
obtained from GST fusion proteins contain small amounts of
GST and possibly E. coli proteins, we generated a control
antiserum against an induced E. coli BL21(DE3)/pLysS/
pGEX-6P-1 cell lysate. Like the preimmune sera, this control
antiserum exhibited an antibody titer toward nHapS-P860295 of
less than 100.
Antibody inhibition of adherence to Chang epithelial cells.
To assess functional characteristics of antisera raised against
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that recognizes an epitope located in the C-terminal one-third of HapS (6).
Bound antibodies were detected with alkaline phosphatase-conjugated goat antimouse immunoglobulin G (IgG) and IgM antibodies (Biosource, Camarillo,
Calif.).
ELISA. The antibody response of mice to rCBD was measured by using a
standard enzyme-linked immunosorbent assay (ELISA) procedure. MaxiSorp
surface Nunc-Immuno 96-well plates (Nalge Nunc International, Naperville, Ill.)
were coated overnight at 37°C with purified nHapS-P860295 diluted to 5 g/ml in
PBS. Antibodies bound to nHapS-P860295 were detected with alkaline phosphatase-conjugated goat anti-mouse IgG and IgM antibodies. Antibody titers
were expressed as the reciprocal of serum dilution with an absorbance of 0.1
extrapolated from a linear plot of the logarithm of absorbance versus the logarithm of serum sample dilution.
Antibody inhibition of adherence. Mouse antisera against rCBD were tested
for their ability to block H. influenzae Hap-mediated adherence to human epithelial cells. In performing these assays, bacteria were grown in BHI broth to late
log phase, pelleted in a microcentrifuge, and resuspended in plain BHI broth
containing an antiserum with a 1:100 dilution. After incubation for 30 min at
room temperature, 1 ⫻ 107 to 2 ⫻ 107 CFU were inoculated onto monolayers of
Chang conjunctival epithelial cells (Wong-Kilbourne derivative, clone 1-5c-4
[human conjunctiva]), and adherence was measured as described previously (22).
Percent adherence was calculated by dividing the number of adherent CFU per
monolayer by the number of inoculated CFU. Preimmune serum and antiserum
against an induced E. coli BL21(DE23)/pLysS/pGEX-6P-1 cell lysate were tested
as negative controls.
Subcutaneous immunization. Groups of 10 female, 6- to 8-week-old Swiss
Webster or BALB/c mice (Taconic Farms, Germantown, N.Y.) were immunized
subcutaneously at weeks 0 and 4 with protein antigens. To prepare the protein
antigens for vaccination, 10 g of rCBD or 2 g of an induced E. coli
BL21(DE23)/pLysS/pGEX-6P-1 cell lysate was absorbed onto 100 g of aluminum phosphate at 37° for 1 h, and then 50 g of 3-O-deacylated monophosphoryl
lipid A (MPL; Corixa Corp., Hamilton, Mont.) was added. Sera collected at
weeks 0, 4, and 6 were pooled for analysis.
Intranasal immunization. Groups of 10 female, 6-week-old BALB/c mice
were immunized intranasally with protein antigens as described previously (5) at
weeks 0, 1, 3, and 5. To prepare the protein antigens for vaccination, 15 g of
rCBD was diluted in Dulbecco’s PBS (D-PBS) to a final volume of 20 to 40 l
with or without 0.1 g of CT-E29H (a mutant cholera toxin) as an adjuvant (24).
Control mice received D-PBS alone or D-PBS with 0.1 g of CT-E29H. Sera
collected at weeks 0, 3, 5, and 8 were pooled for analysis. Prior to immunization,
mice were anesthetized with a mixture of ketamine (80 mg per kg of body weight)
and xylazine (7 mg per kg of body weight), a dosage that maintains a state of
anesthesia for 15 to 20 min. Vaccines were delivered by pipette in a volume of 20
l per nostril. The pipette was positioned so that the tip touched the opening of
the nostril, allowing the liquid to be drawn into the nasopharynx with breathing.
Immediately following immunization, mice were placed in a supine position for
3 to 5 min.
Intranasal challenge. Three weeks after the final immunization, mice were
challenged intranasally with approximately ⫻106 CFU of strain TN106.P2 as
described previously (5). To determine the actual bacterial count of the inoculum, an aliquot of the bacterial suspension was diluted in D-PBS and plated on
BHI-XV plates. Three days after challenge, mice were sacrificed and the nasal
tissue was harvested, weighed, homogenized, and plated on BHI-XV plates
containing 100 g of streptomycin/ml. The plates were incubated overnight, and
the colonies were counted. The data were expressed as log CFU per gram of
nasal tissue. The variability of the standard errors of the means between the
groups in the present study violates the assumption of equal variance between
groups, making it more appropriate to first rank the data and then use an analysis
of variance. Accordingly, statistical differences among groups were analyzed by
use of the Tukey-Kramer test, a nonparametric method applied when data points
are not normally distributed (3, 4).
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TABLE 1. Antibody responsea elicited by rCBD via
subcutaneous immunization
Antiserum against rCBDb derived from

Antibody titer to
nHaps-P860295

GST-rCBDN187 FP.................................................................... 58,050
GST-rCBDP860295 FP................................................................ 97,739
GST-rCBDTN106 FP.................................................................. 14,833
rCBDN187 IB.............................................................................. 32,440

a
Mice were immunized subcutaneously with rCBD mixed with MPL and
aluminum phosphate. Preimmune era and week 6 sera pooled from 10 mice were
analyzed for antibody titer to purified nHapS-P860295.
b
rCBD was generated from soluble GST-rCBD fusion protein (FP) or ureasolubilized inclusion bodies (IB).
c
Control antiserum against an induced BL21 (DE3)/pLysS/pGEX-6P-1 cell
lysate.

rCBD derived from GST fusion protein, we examined their
effect on H. influenzae Hap-mediated adherence. Both strains
DB117/HapP860295 (Fig. 2A) and DB117/HapN187 (Fig. 2B)
exhibited appreciable adherence to Chang cells, well above the
background level of adherence by the DB117/pGJB103 control. Adherence by DB117/HapP860295 was reduced significantly by preincubation with anti-nHapS-P860295 serum (Fig.
2A). Similar decreases in adherence were observed with
DB117/HapP860295 preincubated with anti-rCBDP860295 serum
(Fig. 2A) and with DB117/HapN187 preincubated with antirCBDN187 serum (Fig. 2B). In contrast, adherence by DB117/
HapP860295 or DB117/HapN187 was unaffected by preincubation with preimmune serum (Fig. 2A and B). Additional
control experiments using antiserum against an induced E. coli
BL21(DE3)/pLysS/pGEX-6P-1 cell lysate also showed no effects on adherence of DB117/HapP860295 or DB117/HapN187
(data not shown). These findings suggest that nHapS-P860295,
rCBDP860295, and rCBDN187 elicit antibodies capable of blocking Hap-mediated adherence to human epithelial cells.
Effect of immunization with rCBD on nasopharyngeal colonization. To investigate if immunization with rCBD would
affect nasopharyngeal colonization by H. influenzae, rCBDN187,
rCBDP860295, and rCBDTN106 generated from GST fusion proteins were administered intranasally to mice. Upon challenge
with strain TN106, a significant reduction in nasal colonization
was observed in mice immunized with rCBDP860295 compared
to that of the control group D-PBS (Fig. 3A). Further reduction in nasal colonization was detected in mice immunized with
rCBDP860295 together with CT-E29H adjuvant compared to
that of the control groups D-PBS plus CT-E29H and D-PBS
plus vaccine buffer. The same pattern was noted for mice
immunized with either rCBDN187 (Fig. 3B) or rCBDTN106 (Fig.
3C). These results demonstrate that rCBD derived from strains
P860295, N187, and TN106 can elicit antibodies capable of
reducing nasopharyngeal colonization by strain TN106.
Antisera from intranasally immunized mice were tested for
antibody response to nHapS purified from strain P860295. After four immunizations, mice that received either rCBDN187 or
rCBDP860295 had high antibody titers to nHapS-P860295 (Table
2). The anti-nHapS-P860295 antibody titer was increased by
threefold when rCBDN187 was delivered with CT-E29H adjuvant. In contrast, no such adjuvant effect was observed with

FIG. 2. (A) Adherence to monolayers of Chang conjunctival epithelial cells by strains DB117/pGJB103 (vector), DB117/HapP860295,
and DB117/HapP860295 that had been preincubated with either preimmune serum, antiserum against nHapS-P860295, or antiserum against
rCBDP860295 derived from GST fusion protein (FP). **, P ⬍ 0.05
compared to DB117/HapP860295 plus preimmune serum. (B) Adherence to monolayers of Chang conjunctival epithelial cells by strains
DB117/pGJB103, DB117/HapN187, and DB117/HapN187 that had been
preincubated with either preimmune serum, antiserum against
rCBDN187 derived from GST fusion protein (FP), or antiserum against
rCBDN187 isolated from inclusion bodies (IB). **, P ⬍ 0.05 compared
to DB117/HapN187 plus preimmune serum. In both panels, each bar
represents the means ⫾ standard error of the means of measurements
made in triplicate from a representative experiment.
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TABLE 2. Antibody responsea elicited by rCBD via
intranasal immunization
Antibody
titer to
nHapS-P860295

GST-rCBDN187 FP

D-PBS/none
D-PBS/CT-E29H

8,120
27,240

GST-rCBDP860295 FP

D-PBS/none
D-PBS/CT-E29H

21,175
20,659

None
None

D-PBS/none
D-PBS/CT-E29H

⬍100
⬍100

Preimmune sera

NAc

⬍100

a
Mice were immunized intranasally with rCBD mixed with D-PBS or adjuvant
CT-E29H. Preimmune sera and week 8 sera pooled from 15 mice were analyzed
for antibody titer toward purified nHapS-P860295.
b
rCBD was generated from soluble GST-rCBD fusion protein (FP).
c
NA, not applicable.

rCBDP860295. These results demonstrate that intranasal immunization with rCBD elicits antibodies that cross-react with
nHapS-P860295.
Antibody response elicited by rCBDN187 derived from inclusion bodies. Because it is impractical to produce large quantities of pure rCBD from GST fusion protein, we constructed an
E. coli strain that overproduces rCBDN187 under the control of
an IPTG-inducible T7 expression system. The amount of
rCBDN187 represented 43% of the total protein of induced
cells (Fig. 4, lane 2). The bulk of rCBDN187 formed inclusion
bodies with a purity of greater than 92% (Fig. 4, lane 4). The
inclusion bodies were extracted with urea, and urea-solubilized
rCBDN187 was renatured in a dilute state at 10°C in the presence of 0.4 M L-arginine. Renatured rCBDN187 required 0.1 M
L-arginine and 0.5% of Triton X-100 to remain soluble upon
repeated cycles of freeze and thaw from storage at ⫺20°C.
Mice immunized once with rCBDN187 derived from inclusion bodies had an anti-nHapS-P860295 antibody titer of 2,053,
which was boosted almost 16-fold by a second immunization
(Table 1). This antibody response demonstrates that renatured
rCBDN187 resembles rCBDN187 generated from soluble GST
fusion protein, capable of eliciting antibodies that cross-react
with nHapS-P860295. The antiserum against renatured
rCBDN187 also exhibited moderate titers toward whole cells of
NTHi strains N187, P860295, TN106, SR7332, and P861454
while the preimmune sera showed titers of less than 100 (data
not shown), suggesting that antibodies elicited by renatured

FIG. 3. Nasopharyngeal colonization by strain TN106.P2 in
BALB/c mice immunized with rCBD derived from GST fusion proteins. (A) Bacterial colonization in mice vaccinated with rCBDP860295.
(B) Bacterial colonization in mice vaccinated with rCBDN187. (C) Bacterial colonization in mice vaccinated with rCBDTN106. In panel A, an
asterisk indicates significant difference from D-PBS control and two
asterisks indicates significant difference from D-PBS plus CT-E29H
and D-PBS plus vaccine buffer controls. In panels B and C, an asterisk
indicates significant difference from D-PBS control and two asterisks
indicates significant difference from D-PBS plus CT-E29H control.
The x axis represents the detection limit of the assay, and each bar
represents the standard error of the means.
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FIG. 5. Nasopharyngeal colonization by strain TN106.P2 in
BALB/c mice immunized with rCBDN187 renatured from urea-solubilized inclusion bodies. *, significant difference from D-PBS control; **,
significant difference from D-PBS plus CT-E29H and D-PBS plus
vaccine buffer controls. The x axis represents the detection limit of
assay, and each bar represents the standard error of the means.

rCBDN187 are cross-reactive with surface-exposed Hap of heterologous strains.
Inhibition of adherence to Chang epithelial cells by antibodies against rCBDN187 derived from inclusion bodies. The
antiserum raised against rCBDN187 isolated from inclusion
bodies was tested in the in vitro adherence assay. As shown in
Fig. 2B, strain DB117/HapN187 readily adhered to Chang cells,
and this adherence was markedly reduced by preincubation
with anti-rCBDN187 serum, indicating that, similar to rCBD
generated from soluble GST fusion protein, rCBDN187 derived
from inclusion bodies was also able to elicit functional antibodies that block HapN187-mediated adherence of H. influenzae to human epithelial cells.
Effect of immunization with rCBDN187 derived from inclusion bodies on nasopharyngeal colonization. Mice immunized
intranasally with rCBDN187 isolated from inclusion bodies
were challenged with strain TN106 as described in Materials
and Methods. A significant reduction in nasal colonization was
observed in mice that received renatured rCBDN187 compared
to that of the control group D-PBS (Fig. 5). This level of
colonization was further reduced to the limit of detection when
renatured rCBDN187 was administered with CT-E29H compared to that of the control groups D-PBS plus CT-E29H and
D-PBS plus vaccine buffer. These results demonstrate that
rCBDN187 derived from inclusion bodies, just like rCBD generated from soluble GST fusion protein elicits cross-reacting
antibodies capable of reducing nasopharyngeal colonization by
strain TN106.

that facilitates bacterial colonization. The Hap protein is one
such adhesin, promoting bacterial aggregation, microcolony
formation, and adherence to human respiratory epithelial cells
and extracellular matrix proteins. The HapS portion of Hap
harbors all adhesive activities, making HapS an attractive vaccine candidate. Furthermore, antibodies against HapS have
been shown to impede colonization by H. influenzae in an
animal model (5). The recent finding that the C-terminal 311
amino acid residues of HapS retain the functional domain
essential for adherence to human epithelial cells and formation
of microcolonies (6) prompted us to examine this fragment for
its vaccine potential.
While many surface-exposed proteins of NTHi are highly
variable, HapS appears to be similar among strains, based on
the homology of available hap gene sequences (5). Protein
sequence alignment of the C-terminal binding domain of HapS
from strains P860295, N187, and TN106 indicates that the
CBD region is highly conserved. However, it was unclear
whether this degree of homology would be sufficient for CBD
from one strain to elicit functional antibodies that are crossreactive with HapS of other strains. To determine if CBD
derived from more than one strain would be required for
generating protective immunity against multiple strains, we
examined the immune response of mice to rCBD from these
three strains.
Initially we constructed E. coli strains to express CBD as
GST fusion protein, taking advantage of the commercially
available protease and affinity matrix for purifying target proteins from their GST fusion counterparts. To avoid complications due to insolubility, rCBD was isolated from GST fusion
protein that remained soluble. Although rCBD is the major
species in these affinity-purified preparations, high purity was
not achieved. Nevertheless, the small amounts of GST and

DISCUSSION
To establish infection, H. influenzae utilizes adhesive molecules to interact with tissues of the respiratory tract, a process

Downloaded from http://iai.asm.org/ on January 29, 2014 by Washington University in St. Louis

FIG. 4. Subcellular location of rCBDN187 produced by E. coli
BL21(DE3)/pWV1024. Coomassie-stained gel showing cell lysate
(lane 2) of an IPTG-induced culture, cytosolic and membrane proteins
(lane 3), and urea-solubilized rCBDN187 inclusion bodies (lane 4). The
amount of sample loaded in each lane is equivalent to 20 l of culture.
Lane 1 shows Bio-Rad prestained low-molecular-mass markers (in
kilodaltons).
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CBD from HapN187 was selected for further investigation
based on good expression levels in pilot experiments.
rCBDN187 under the control of T7 promoter was overproduced
as inclusion bodies. The inclusion bodies were readily solubilized by urea with a purity of greater than 92% (Fig. 4). Utilizing L-arginine to assist protein renaturation, renatured
rCBDN187 remained soluble above 1 mg/ml. Just like rCBD
derived from GST-fusion proteins, renatured rCBDN187 elicited antibodies that are not only cross-reactive with purified
nHapS-P860295 but also are capable of blocking Hap-mediated
adherence of strain DB117/HapN187 to Chang cells (Fig. 2B).
Most importantly, intranasal immunization of mice with renatured rCBDN187 significantly reduced nasopharyngeal colonization by strain TN106 (Fig. 5). The high purity of rCBDN187
preparations shows that the immune response to rCBD is responsible for these functional activities both in vitro and in
vivo. These results clearly demonstrate that rCBDN187 solubilized and renatured from inclusion bodies is a potential vaccine
candidate against H. influenzae infection.
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presumed E. coli proteins did not contribute to the immune
response elicited by rCBD, because the antiserum against an
induced E. coli BL21(DE3)/pLysS/pGEX-6P-1 cell lysate, resembling the preimmune sera, exhibited an antibody titer of
less than 100 toward nHapS-P860295. Therefore, the significant
titers observed with the antisera against rCBDP860295,
rCBDN187, and rCBDTN106 derived from soluble GST fusion
protein demonstrate that, indeed, anti-rCBD antibodies are
cross-reactive with nHapS-P860295.
Using in-frame deletion derivatives of Hap expressed by
DB117, Fink et al. established that the C-terminal 311 amino
acids of HapS mediate H. influenzae adherence to human epithelial cells (6). In addition, they reported that MAb 314
inhibits HapS-mediated bacterial adherence to both A549 cells
and Chang cells, suggesting that the epitope recognized by
MAb 314 is located nearby the adhesive domain. In this study
we found that MAb 314 is reactive with rCDB from strains
P860295 (Fig. 1B), N187, and TN106 (data not shown), indicating that the 314 epitope is in a conserved region of CBD.
More importantly, antibodies elicited by rCBDP860295 and
rCBDN187 block Hap-mediated adherence of DB117/Hap to
Chang cells (Fig. 2), while antiserum against an induced E. coli
cell lysate had no effects on adherence. These results imply that
the adherence-blocking activity of anti-nHap sera previously
reported (7) is attributed to anti-rCBD antibodies.
Intranasal immunization has been utilized to demonstrate
the potential of vaccine candidates against H. influenzae infections (11, 12). Because otitis media is a mucosal surface disease, intranasal immunization may be the preferred route for
humans. While mice immunized intranasally with native HapS
purified from strain P860295 or N187 showed significant reductions in nasopharyngeal colonization by strain TN106 (5),
it was unclear which portion(s) of HapS was responsible for
generating such cross-reactive immune responses. In this investigation, we used the same murine model to test rCBD.
Intranasal immunization with either rCBDN187 or rCBDP860295
elicited antibodies that were reactive with purified nHapS-P860295
(Table 2). Furthermore, mice immunized intranasally with
rCBDP860295, rCBDN187, or rCBDTN106 exhibited significant
decreases in nasopharyngeal colonization by TN106, and the
reduction was lowered still further when rCBD was administered with CT-E29H (Fig. 3). These results suggest that an
rCBD generated from soluble GST fusion protein, regardless
of the strain, assumes a proper conformation to elicit antibodies that are cross-reactive and functional in the in vitro adherence assay as well as in the in vivo challenge model.
Obstacles to developing a HapS-based vaccine are twofold.
At the cellular level, H. influenzae does not produce large
amounts of HapS. Thus, it is impractical to purify native HapS
for vaccine use. At the protein level, HapS tends to form
aggregates at even moderate concentrations, making handling
of the protein a challenge. Although protein solubility is substantially improved by expressing only the N-terminal 311
amino acids of HapS as a GST fusion protein, producing rCBD
from GST fusion protein as a vaccine component is not a
desirable approach because of processing issues. Moreover,
rCBD purified by affinity chromatography contains small
amounts of uncleaved fusion protein, rCBD breakdown products, GST, and possibly E. coli proteins. Therefore, we sought
to generate a non-fusion-derived rCBD of much greater purity.
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